
Dr Merja Joensuu (R) and a colleague, look at cells through a microscope.
Photo Credit: The University of Queensland
Scientific Frontline: Extended "At a Glance" Summary: NMT1 Antiviral Pathway Breakthrough
The Core Concept: A novel antiviral treatment strategy that inhibits the human enzyme N-myristoyltransferase 1 (NMT1) to prevent viruses from successfully assembling and replicating inside host cells.
Key Distinction/Mechanism: Traditional antivirals target the pathogen directly, which frequently leads to viral mutation and drug resistance. This new approach instead disrupts the human cellular pathway that viruses hijack during reproduction. By altering host cell function, the targeted pathway forces the cell to produce defective, less-effective viral particles, granting the immune system critical time to clear the infection.
Major Frameworks/Components:
- Enzymatic Target: The therapy utilizes a compound—currently undergoing clinical trials as a cancer treatment—to inhibit NMT1, an enzyme responsible for directing protein location and function within cells.
- Viral Assembly Disruption: By altering spatial organization and cellular function, the drug ensures that new viral copies are constructed incorrectly.
- Broad-Spectrum Efficacy: Laboratory cell culture tests demonstrated significant efficacy against diverse infectious agents, including SARS-CoV-2, respiratory syncytial virus (RSV), and vesicular stomatitis virus.
- Rapid Pathogen Reduction: Researchers observed viral infection levels drop by approximately 50 percent after one day, and up to 90 percent after two days.








.png)






.jpg)


